Our Offerings
By Industry By Function
About Us
Our Viewpoint
NEW
 Senior Management Experts Panel Global Consultants Press Releases Blog
Infographics Market Insights Case Studies Illustrations In The Press
Contact Us
The Business Research Company Logo
Reports Store
Top 50 Healthcare Market Reports
NEW
 Top 50 Non-Healthcare Market Reports
NEW
 Opportunities And Strategies Reports Aerospace And Defense Agriculture Chemicals Construction
Electrical And Electronics Financial Services Food And Beverages Healthcare Services Hospitality Information Technology Machinery Media
Medical Equipment Metal And Mineral Mining Oil And Gas Paper, Plastics, Rubber, Wood And Textile Pharmaceuticals Professional Services Recreation
Retail And Wholesale Services Social Services Transport Transport Services Utilities Veterinary Healthcare Filter Reports by Trends
NEW
Market Intelligence Platform
About GMM Global Forecast
NEW
 Mega Trends Analysis
Consultancies Corporate Planning & Strategy Academic Financial Services Legal Services
Pricing Methodology Sources FAQ Press Coverage
Customized Research
Find Customers Optimise Your Marketing Mix Evaluate Competitors Identify Market Opportunities Develop Products And Services
Distributor And Partner Research Plan Finances Streamline Your Operations Devise Market Entry Strategy Explore Custom Research Packages
NEW
Continuous Research
Desk Research Research Reports Senior Executive Interviews Consumer Research Market Sizing And Forecasts
Company Information Analytics And Data Visualization Research Automation Web Crawling And Spidering AI-Empowered Research Services
Request Proposal
Ischemic Heart Disease (IHD) Drugs Global Market Report 2025
Request Sample Buy Now
Global Ischemic Heart Disease (IHD) Drugs Market Report 2025

Report Price : $4490.00

Pages : 175

Format : PDF

Published : January 2025

Delivery Time : 2-3 Business Days

Purchase This Report
Purchase This Report

Ischemic Heart Disease (IHD) Drugs Global Market Report 2025

By Drug Class (Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasodilators, Antithrombotic Agents), By Disease Class (Angina Pectoris, Myocardial Infarction), By End User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Ischemic Heart Disease (IHD) Drugs Market Overview

• Ischemic Heart Disease (IHD) Drugs market size has reached to $6.36 billion in 2024

• Expected to grow to $7.7 billion in 2029 at a compound annual growth rate (CAGR) of 3.7%

• Growth Driver: Rising Prevalence Of Obesity And Diabetes Fuels Expansion Of The Ischemic Heart Disease (IHD) Drugs Market

• Market Trend: Emerging Cardiac Myosin Inhibitors Offer New Therapeutic Potential for Ischemic Heart Disease

• North America was the largest region in 2024 and Asia-Pacific is the fastest growing region.

What Is Covered Under Ischemic Heart Disease (IHD) Drugs Market?

Ischemic heart disease (IHD) drugs are medications used to manage and treat a condition characterized by reduced blood flow to the heart muscle, often due to coronary artery narrowing. These drugs aim to alleviate symptoms, reduce the risk of complications such as heart attacks, and improve overall cardiac function.

The main types of drug classes included in ischemic heart disease (IHD) drugs are anti-dyslipidemic drugs, calcium channel blockers, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), vasodilators, and antithrombotic agents. Anti-dyslipidemic drugs are pharmacological agents that target and lower abnormal levels of lipids (such as cholesterol and triglycerides) in the bloodstream to reduce the risk of cardiovascular disease. These are used to treat various classes of disease, including angina pectoris and myocardial infarction, and are used by several end users, such as hospital pharmacies, retail pharmacies, and online pharmacies.

Ischemic Heart Disease (IHD) Drugs Market Size and growth rate 2025 to 2029: Graph

What Is The Ischemic Heart Disease (IHD) Drugs Market Size 2025 And Growth Rate?

The ischemic heart disease (IHD) drugs market size has grown strongly in recent years. It will grow from $6.36 billion in 2024 to $6.65 billion in 2025 at a compound annual growth rate (CAGR) of 4.5%. The growth in the historic period can be attributed to rising global prevalence of ischemic heart disease, increased awareness and diagnostics, changes in lifestyle and dietary patterns, government initiatives for cardiovascular health, collaborations for clinical trials, insurance coverage and reimbursement policies.

What Is The Ischemic Heart Disease (IHD) Drugs Market Growth Forecast?

The ischemic heart disease (IHD) drugs market size is expected to see steady growth in the next few years. It will grow to $7.7 billion in 2029 at a compound annual growth rate (CAGR) of 3.7%. The growth in the forecast period can be attributed to aging population trends, personalized medicine approaches, emphasis on cardiovascular prevention, global health policies and initiatives, international research collaborations. Major trends in the forecast period include shift towards precision medicine approaches, focus on novel anti-atherogenic agents, advancements in lipid-lowering therapies, integration of anti-inflammatory agents, development of antithrombotic and antiplatelet drugs.

The forecast of 3.7% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade restrictions could burden cardiology practices by inflating prices of antianginal medications manufactured in Ireland and Japan, resulting in delayed coronary artery disease management and higher cardiovascular treatment costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

What’s The Trade War Impact On Pharmaceuticals Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

How Is The Ischemic Heart Disease (IHD) Drugs Market Segmented?

1) By Drug Class: Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasodilators, Antithrombotic Agents

2) By Disease Class: Angina Pectoris, Myocardial Infarction

3) By End User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Anti-Dyslipidemic Drugs: Statins, Fibrates, Niacin, Cholesterol Absorption Inhibitors

2) By Calcium Channel Blockers: Dihydropyridines, Non-Dihydropyridines

3) By Beta-Blockers: Cardioselective Beta-Blockers, Non-Selective Beta-Blockers, Vasodilating Beta-Blockers

4) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril, Lisinopril, Ramipril

5) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan

6) By Vasodilators: Nitroglycerin, Isosorbide Dinitrate, Hydralazine

7) By Antithrombotic Agents: Antiplatelet Drugs, Anticoagulants

What Is Driving The Ischemic Heart Disease (IHD) Drugs Market? Rising Prevalence Of Obesity And Diabetes Fuels Expansion Of The Ischemic Heart Disease (IHD) Drugs Market

The growing prevalence of obesity and diabetes is expected to propel the growth of the ischemic heart disease (IHD) drugs market going forward. Diabetes is a long-term metabolic disease that causes high blood glucose levels, and obesity is a medical condition characterized by an excessive accumulation of body fat that can negatively impact health. Ischemic heart disease drugs are often used in individuals with obesity and diabetes to manage cardiovascular risk factors such as hypertension and dyslipidemia, mitigating the risk of ischemic heart disease. For instance, in 2022, according to the World Obesity Federation, the UK-based Federation that drives global efforts to reduce, prevent, and treat obesity, one billion people globally, including 1 in 5 women and 1 in 7 men, will be living with obesity by 2030. For instance, in June 2024, according to the National Health Service, a UK-based government department, in 2023, the NHS identified over half a million (549,000) additional individuals in England at risk of developing type 2 diabetes, bringing the total number of people with non-diabetic hyperglycemia, or pre-diabetes, registered with a GP to 3,615,330. This represents a significant increase compared to 3,065,825 in 2022, highlighting a rise of nearly 20%. Therefore, the growing prevalence of obesity and diabetes drives the growth of the ischemic heart disease (IHD) drugs industry.

What Is Driving The Ischemic Heart Disease (IHD) Drugs Market? Rising Heart Failure Cases Drive Surge In Ischemic Heart Disease (IHD) Drugs Market Growth

The increasing incidence of heart failure is expected to propel the growth of the ischemic heart disease (IHD) drug market going forward. Heart failure is a chronic condition in which the heart muscle is unable to pump enough blood to meet the body's needs for blood and oxygen. This can lead to fatigue, shortness of breath, and difficulty performing everyday activities. Ischemic heart disease (IHD) drugs play an important role in the treatment of heart failure. To reduce the risk factors and symptoms of ischemic heart disease, these medications can help avoid heart failure. Ischemic Heart Disease (IHD) drugs inhibit the pacemaker activity of the heart and are beneficial in heart failure patients with reduced ejection fractions and high resting heart rates after a tolerated beta-blocker. For instance, in September 2023, according to the Heart Failure Society of America, a US-based organization, 6.7 million Americans over 20 years of age have heart failure (HF), and the prevalence is expected to rise to 8.5 million Americans by 2030. Therefore, the increasing incidence of heart failure is driving the growth of the ischemic heart disease (IHD) drug industry.

Who Are The Major Players In The Global Ischemic Heart Disease (IHD) Drugs Market?

Major companies operating in the ischemic heart disease (IHD) drugs market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sandoz Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Cipla Limited, Lupin Limited, Recordati S.p.A., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alembic Pharmaceuticals Ltd., Eagle Pharmaceuticals Inc., Accord Healthcare Limited, Macleods Pharmaceuticals Ltd., WG Critical Care LLC, Novitium Pharma LLC

What Are The Key Trends Of The Global Ischemic Heart Disease (IHD) Drugs Market? Emerging Cardiac Myosin Inhibitors Offer New Therapeutic Potential for Ischemic Heart Disease

Major companies operating in the ischemic heart disease (IHD) drugs market are increasing their focus on developing innovative myosin inhibitor, to gain a competitive edge in the market. A cardiac myosin inhibitor is a drug that reduces myosin activity in the heart muscle, lowering contraction force. It’s beneficial for conditions like hypertrophic cardiomyopathy (HCM), where excessive muscle thickening impairs heart function. For instance, in April 2022, Bristol Myers Squibb, a US-based pharmaceutical company, launched Camzyos (mavacamten). It is the first cardiac myosin inhibitor approved for the treatment of adults with symptomatic new york heart association class ii-iii obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms. The drug works as an allosteric and reversible inhibitor selective for cardiac myosin, reducing hypercontractility, left ventricular hypertrophy, and improving cardiac filling pressures. This helps decrease dynamic left ventricular outflow tract (LVOT) obstruction.

Need data on a specific region in this market?
Request Customisation

What Are Latest Mergers And Acquisitions In The Ischemic Heart Disease (IHD) Drugs Market? Novo Nordisk Strengthens Cardiovascular Portfolio with Acquisition of Cardior Pharmaceuticals

In March 2024, Novo Nordisk, a Denmark-based pharmaceutical company, acquired cardior pharmaceuticals for an undisclosed amount. The acquisition is a significant step in Novo Nordisk's strategy to establish and expand its portfolio in cardiovascular disease, which is a leading cause of mortality worldwide. Cardior pharmaceuticals is a Germany-based pharmaceutical company manufacturing cardiovascular drugs for IHD.

Regional Outlook For The Global Ischemic Heart Disease (IHD) Drugs Market

North America was the largest region in the ischemic heart disease (IHD) drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Ischemic Heart Disease (IHD) Drugs Market?

The ischemic heart disease (IHD) drugs market consists of sales of antiarrhythmic drugs, anticoagulants, anti-anginal medications, nitroglycerin and nitrates, statins, and antiplatelet agents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Ischemic Heart Disease (IHD) Drugs Industry?

The ischemic heart disease (ihd) drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the ischemic heart disease (ihd) drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Ischemic Heart Disease (IHD) Drugs Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2025 $6.65 billion
Revenue Forecast In 2034 $7.7 billion
Growth Rate CAGR of 3.7% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered 1) By Drug Class: Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasodilators, Antithrombotic Agents
2) By Disease Class: Angina Pectoris, Myocardial Infarction
3) By End User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy Subsegments: 1) By Anti-Dyslipidemic Drugs: Statins, Fibrates, Niacin, Cholesterol Absorption Inhibitors
2) By Calcium Channel Blockers: Dihydropyridines, Non-Dihydropyridines
3) By Beta-Blockers: Cardioselective Beta-Blockers, Non-Selective Beta-Blockers, Vasodilating Beta-Blockers
4) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril, Lisinopril, Ramipril
5) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan 6) By Vasodilators: Nitroglycerin, Isosorbide Dinitrate, Hydralazine 7) By Antithrombotic Agents: Antiplatelet Drugs, Anticoagulants
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sandoz Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Cipla Limited, Lupin Limited, Recordati S.p.A., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alembic Pharmaceuticals Ltd., Eagle Pharmaceuticals Inc., Accord Healthcare Limited, Macleods Pharmaceuticals Ltd., WG Critical Care LLC, Novitium Pharma LLC
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

2. Ischemic Heart Disease (IHD) Drugs Market Characteristics

3. Ischemic Heart Disease (IHD) Drugs Market Trends And Strategies

4. Ischemic Heart Disease (IHD) Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Ischemic Heart Disease (IHD) Drugs Growth Analysis And Strategic Analysis Framework

5.1. Global Ischemic Heart Disease (IHD) Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Ischemic Heart Disease (IHD) Drugs Market Growth Rate Analysis

5.4. Global Ischemic Heart Disease (IHD) Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Ischemic Heart Disease (IHD) Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Ischemic Heart Disease (IHD) Drugs Total Addressable Market (TAM)

6. Ischemic Heart Disease (IHD) Drugs Market Segmentation

6.1. Global Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Anti-Dyslipidemic Drugs

Calcium Channel Blockers

Beta-Blockers

Angiotensin-converting enzyme (ACE) Inhibitors

Angiotensin II Receptor Blockers (ARBs)

Vasodilators

Antithrombotic Agents

6.2. Global Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Angina Pectoris

Myocardial Infarction

6.3. Global Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

6.4. Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Anti-Dyslipidemic Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Statins

Fibrates

Niacin

Cholesterol Absorption Inhibitors

6.5. Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Calcium Channel Blockers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Dihydropyridines

Non-Dihydropyridines

6.6. Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Beta-Blockers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Cardioselective Beta-Blockers

Non-Selective Beta-Blockers

Vasodilating Beta-Blockers

6.7. Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Angiotensin-Converting Enzyme (ACE) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Enalapril

Lisinopril

Ramipril

6.8. Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Angiotensin II Receptor Blockers (ARBs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Losartan

Valsartan

Irbesartan

6.9. Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Vasodilators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Nitroglycerin

Isosorbide Dinitrate

Hydralazine

6.10. Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Antithrombotic Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Antiplatelet Drugs

Anticoagulants

7. Ischemic Heart Disease (IHD) Drugs Market Regional And Country Analysis

7.1. Global Ischemic Heart Disease (IHD) Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Ischemic Heart Disease (IHD) Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Ischemic Heart Disease (IHD) Drugs Market

8.1. Asia-Pacific Ischemic Heart Disease (IHD) Drugs Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Ischemic Heart Disease (IHD) Drugs Market

9.1. China Ischemic Heart Disease (IHD) Drugs Market Overview

9.2. China Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Ischemic Heart Disease (IHD) Drugs Market

10.1. India Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Ischemic Heart Disease (IHD) Drugs Market

11.1. Japan Ischemic Heart Disease (IHD) Drugs Market Overview

11.2. Japan Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Ischemic Heart Disease (IHD) Drugs Market

12.1. Australia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Ischemic Heart Disease (IHD) Drugs Market

13.1. Indonesia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Ischemic Heart Disease (IHD) Drugs Market

14.1. South Korea Ischemic Heart Disease (IHD) Drugs Market Overview

14.2. South Korea Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Ischemic Heart Disease (IHD) Drugs Market

15.1. Western Europe Ischemic Heart Disease (IHD) Drugs Market Overview

15.2. Western Europe Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Ischemic Heart Disease (IHD) Drugs Market

16.1. UK Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Ischemic Heart Disease (IHD) Drugs Market

17.1. Germany Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Ischemic Heart Disease (IHD) Drugs Market

18.1. France Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Ischemic Heart Disease (IHD) Drugs Market

19.1. Italy Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Ischemic Heart Disease (IHD) Drugs Market

20.1. Spain Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Ischemic Heart Disease (IHD) Drugs Market

21.1. Eastern Europe Ischemic Heart Disease (IHD) Drugs Market Overview

21.2. Eastern Europe Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Ischemic Heart Disease (IHD) Drugs Market

22.1. Russia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Ischemic Heart Disease (IHD) Drugs Market

23.1. North America Ischemic Heart Disease (IHD) Drugs Market Overview

23.2. North America Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Ischemic Heart Disease (IHD) Drugs Market

24.1. USA Ischemic Heart Disease (IHD) Drugs Market Overview

24.2. USA Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Ischemic Heart Disease (IHD) Drugs Market

25.1. Canada Ischemic Heart Disease (IHD) Drugs Market Overview

25.2. Canada Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Ischemic Heart Disease (IHD) Drugs Market

26.1. South America Ischemic Heart Disease (IHD) Drugs Market Overview

26.2. South America Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Ischemic Heart Disease (IHD) Drugs Market

27.1. Brazil Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Ischemic Heart Disease (IHD) Drugs Market

28.1. Middle East Ischemic Heart Disease (IHD) Drugs Market Overview

28.2. Middle East Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Ischemic Heart Disease (IHD) Drugs Market

29.1. Africa Ischemic Heart Disease (IHD) Drugs Market Overview

29.2. Africa Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Ischemic Heart Disease (IHD) Drugs Market Competitive Landscape And Company Profiles

30.1. Ischemic Heart Disease (IHD) Drugs Market Competitive Landscape

30.2. Ischemic Heart Disease (IHD) Drugs Market Company Profiles

30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Ischemic Heart Disease (IHD) Drugs Market Other Major And Innovative Companies

31.1. Novartis AG

31.2. Sanofi S.A.

31.3. Bristol-Myers Squibb Company

31.4. AstraZeneca PLC

31.5. GSK PLC

31.6. Eli Lilly and Company

31.7. Boehringer Ingelheim International GmbH

31.8. Viatris Inc.

31.9. Baxter International Inc.

31.10. Teva Pharmaceutical Industries Ltd.

31.11. Sandoz Inc.

31.12. Sun Pharmaceutical Industries Limited

31.13. Dr. Reddy's Laboratories Ltd.

31.14. Cipla Limited

31.15. Lupin Limited

32. Global Ischemic Heart Disease (IHD) Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Ischemic Heart Disease (IHD) Drugs Market

34. Recent Developments In The Ischemic Heart Disease (IHD) Drugs Market

35. Ischemic Heart Disease (IHD) Drugs Market High Potential Countries, Segments and Strategies

35.1 Ischemic Heart Disease (IHD) Drugs Market In 2029 - Countries Offering Most New Opportunities

35.2 Ischemic Heart Disease (IHD) Drugs Market In 2029 - Segments Offering Most New Opportunities

35.3 Ischemic Heart Disease (IHD) Drugs Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Anti-Dyslipidemic Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Calcium Channel Blockers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Beta-Blockers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Angiotensin-Converting Enzyme (ACE) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Angiotensin II Receptor Blockers (ARBs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Vasodilators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Antithrombotic Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Global Ischemic Heart Disease (IHD) Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Global Ischemic Heart Disease (IHD) Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: Asia-Pacific, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: Asia-Pacific, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: Asia-Pacific, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: China, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: China, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: China, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: India, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: India, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: India, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Japan, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Japan, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Japan, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Australia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Australia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Australia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: Indonesia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: Indonesia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: Indonesia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: South Korea, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: South Korea, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: South Korea, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: Western Europe, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: Western Europe, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: Western Europe, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: UK, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: UK, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: UK, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: Germany, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: Germany, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: Germany, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: France, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: France, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: France, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Italy, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Italy, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Italy, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Spain, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Spain, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Spain, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Eastern Europe, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Eastern Europe, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Eastern Europe, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: Russia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: Russia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: Russia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: North America, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: North America, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: North America, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: USA, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: USA, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: USA, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: Canada, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: Canada, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: Canada, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: South America, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: South America, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: South America, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Brazil, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Brazil, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Brazil, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Middle East, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Middle East, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Middle East, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Africa, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 79: Africa, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 80: Africa, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 81: Pfizer Inc. Financial Performance
  • Table 82: F. Hoffmann-La Roche Ltd. Financial Performance
  • Table 83: Merck & Co. Inc. Financial Performance
  • Table 84: AbbVie Inc. Financial Performance
  • Table 85: Bayer AG Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Anti-Dyslipidemic Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Calcium Channel Blockers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Beta-Blockers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Angiotensin-Converting Enzyme (ACE) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Angiotensin II Receptor Blockers (ARBs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Vasodilators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Antithrombotic Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Global Ischemic Heart Disease (IHD) Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Global Ischemic Heart Disease (IHD) Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: Asia-Pacific, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: Asia-Pacific, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: Asia-Pacific, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: China, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: China, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: China, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: India, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: India, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: India, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Japan, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Japan, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Japan, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Australia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Australia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Australia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: Indonesia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: Indonesia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: Indonesia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: South Korea, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: South Korea, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: South Korea, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: Western Europe, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: Western Europe, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: Western Europe, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: UK, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: UK, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: UK, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: Germany, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: Germany, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: Germany, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: France, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: France, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: France, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Italy, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Italy, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Italy, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Spain, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Spain, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Spain, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Eastern Europe, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Eastern Europe, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Eastern Europe, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: Russia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: Russia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: Russia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: North America, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: North America, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: North America, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: USA, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: USA, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: USA, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: Canada, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: Canada, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: Canada, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: South America, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: South America, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: South America, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Brazil, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Brazil, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Brazil, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Middle East, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Middle East, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Middle East, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Africa, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 79: Africa, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 80: Africa, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 81: Pfizer Inc. Financial Performance
  • Figure 82: F. Hoffmann-La Roche Ltd. Financial Performance
  • Figure 83: Merck & Co. Inc. Financial Performance
  • Figure 84: AbbVie Inc. Financial Performance
  • Figure 85: Bayer AG Financial Performance

Key Market Drivers, Trends, and Forecast for the Global Non-Steroidal Anti-inflammatory Drugs Industry

Read More About Key Market Drivers, Trends, and Forecast for the Global Non-Steroidal Anti-inflammatory Drugs Industry

Outlook for Non-Therapeutic Biomolecules Market: Key Developments and Future Strategies to 2029

Read More About Outlook for Non-Therapeutic Biomolecules Market: Key Developments and Future Strategies to 2029

Global Pain Management Drugs Market Forecast to Reach $104.19 Billion by 2029, Driven by 5.6% CAGR

Read More About Global Pain Management Drugs Market Forecast to Reach $104.19 Billion by 2029, Driven by 5.6% CAGR

Pericarditis Industry Poised for Rapid Expansion, Projected to Hit $3.37 Billion by 2029

Read More About Pericarditis Industry Poised for Rapid Expansion, Projected to Hit $3.37 Billion by 2029

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

Read More About A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

Read More About A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

Uncover TBRC’s strategic outlook on technological trends, regulatory factors, and market growth in transdermal drug delivery systems.

Read More About Uncover TBRC’s strategic outlook on technological trends, regulatory factors, and market growth in transdermal drug delivery systems.

Explore forecast data, therapeutic advancements, and pipeline progress in TBRC’s Tuberous Sclerosis Drug Market report.

Read More About Explore forecast data, therapeutic advancements, and pipeline progress in TBRC’s Tuberous Sclerosis Drug Market report.

Outdoor Kitchen Appliances Market 2023 – By Product (Cooking Fixtures, Islands And Storage Units, Refrigeration Units, Rangehoods, Sinks And Faucets, Other Products), By Distribution (Offline, Online), By Application (Re...

View Report

Cardiovascular Drugs Global Market Report 2022 – By Type (Anti-Hypertensive Drugs, Hypolipidemics, Anti Thrombotics, Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrhythmic And Anti-Anginal Dru...

View Report

Metabolic Disorders Drugs Global Market Report 2022 – By Type (Anti Diabetics drugs, Anti-Thyroid Drugs, Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)), By Distribution Channel (Hospital Pharmacies, Retai...

View Report

Edge AI Software Global Market Report 2025 – By Component (Solution, Software Tools, Platform, Services, Training And Consulting Services, System Integration Testing, Support And Maintenance), By Data Type (Video And Ima...

View Report

Storage Area Network (SAN) Solutions Global Market Report 2025 – By Component (Software, Hardware, Services), By Server (Hyperscale Server SAN, Enterprise Server SAN), By Technology (Fiber Channel (FC), Fiber Channel Ove...

View Report

Cardiovascular Monitoring And Diagnostic Devices And Equipment Global Market Report 2025 – By Product Type (Cardiopulmonary Stress Testing Systems, ECG Data Management Systems, ECG Monitoring Equipment, ECG Stress Testin...

View Report

Sinus Dilation Devices Global Market Report 2025 – By Product (Balloon Sinus Dilation Devices, Endoscopes, Functional Endoscopic Sinus Surgery (FESS) Instruments Set, Sinus Stents or Implants, Other Products), By Procedu...

View Report

Frequently Asked Questions

Ischemic heart disease (IHD) drugs are medications used to manage and treat a condition characterized by reduced blood flow to the heart muscle, often due to coronary artery narrowing. These drugs aim to alleviate symptoms, reduce the risk of complications such as heart attacks, and improve overall cardiac function. For further insights on this market, request a sample here

The market major growth driver - Rising Prevalence Of Obesity And Diabetes Fuels Expansion Of The Ischemic Heart Disease (IHD) Drugs Market. For further insights on this market, request a sample here

The ischemic heart disease (IHD) drugs market size has grown steadily in recent years. It will grow from $6.36 billion in 2024 to $6.65 billion in 2025 at a compound annual growth rate (CAGR) of 4.5%. The growth in the historic period can be attributed to rising global prevalence of ischemic heart disease, increased awareness and diagnostics, changes in lifestyle and dietary patterns, government initiatives for cardiovascular health, collaborations for clinical trials, insurance coverage and reimbursement policies. The ischemic heart disease (IHD) drugs market size is expected to see steady growth in the next few years. It will grow to " $7.7 billion in 2029 at a compound annual growth rate (CAGR) of 3.7%. The growth in the forecast period can be attributed to aging population trends, personalized medicine approaches, emphasis on cardiovascular prevention, global health policies and initiatives, international research collaborations. Major trends in the forecast period include shift towards precision medicine approaches, focus on novel anti-atherogenic agents, advancements in lipid-lowering therapies, integration of anti-inflammatory agents, development of antithrombotic and antiplatelet drugs. For further insights on this market, request a sample here

The ischemic heart disease (ihd) drugs market covered in this report is segmented –
1) By Drug Class: Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasodilators, Antithrombotic Agents
2) By Disease Class: Angina Pectoris, Myocardial Infarction
3) By End User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy Subsegments:
1) By Anti-Dyslipidemic Drugs: Statins, Fibrates, Niacin, Cholesterol Absorption Inhibitors
2) By Calcium Channel Blockers: Dihydropyridines, Non-Dihydropyridines
3) By Beta-Blockers: Cardioselective Beta-Blockers, Non-Selective Beta-Blockers, Vasodilating Beta-Blockers
4) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril, Lisinopril, Ramipril
5) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan
6) By Vasodilators: Nitroglycerin, Isosorbide Dinitrate, Hydralazine
7) By Antithrombotic Agents: Antiplatelet Drugs, Anticoagulants For further insights on this market, request a sample here

North America was the largest region in the ischemic heart disease (IHD) drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ischemic heart disease (ihd) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on this market, request a sample here.

Major companies operating in the ischemic heart disease (ihd) drugs market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sandoz Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Cipla Limited, Lupin Limited, Recordati S.p.A., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alembic Pharmaceuticals Ltd., Eagle Pharmaceuticals Inc., Accord Healthcare Limited, Macleods Pharmaceuticals Ltd., WG Critical Care LLC, Novitium Pharma LLC. For further insights on this market, request a sample here.

Major trends in this market include Emerging Cardiac Myosin Inhibitors Offer New Therapeutic Potential for Ischemic Heart Disease. For further insights on this market, request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us
Global Ischemic Heart Disease (IHD) Drugs Market Report 2025

Wait, we have a special offer for you! ✋

Get your exclusive 20% discount only on the Global Market Reports now using the code ONLINE20*

YES, get the discount! No, I'd pay the full price

*Copy paste the discount code in the cart

Back to top WhatsApp icon